Leukemia Research
Volume 36, Issue 3 , Pages 264-270, March 2012

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop

  • Uwe Platzbecker

      Affiliations

    • Universitätsklinikum Carl-Gustav-Carus, Medizinische Klinik I, Dresden 01307, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 351 458 4190; fax: +49 351 458 5362.
    • ,
  • Valeria Santini

      Affiliations

    • AOU Careggi, University of Florence, Italy
    • ,
  • Ghulam J. Mufti

      Affiliations

    • Kings College London and Kings College Hospital, Department of Haematological Medicine, London, UK
    • ,
  • Claudia Haferlach

      Affiliations

    • MLL Munich Leukemia Laboratory, Munich, Germany
    • ,
  • Jaroslaw P. Maciejewski

      Affiliations

    • Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    • ,
  • Sophie Park

      Affiliations

    • Hôpital Cochin, Université, Paris V, Assistance Publique des Hopitaux de Paris, Paris, France
    • ,
  • Francesc Solé

      Affiliations

    • Hospital del Mar-Parc de Salut Mar, Barcelona, Spain
    • ,
  • Arjan A. van de Loosdrecht

      Affiliations

    • Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Detlef Haase

      Affiliations

    • Department of Hematology and Oncology, Georg-August-University, Göttingen, Germany

Received 15 September 2011; received in revised form 7 November 2011; accepted 8 November 2011. published online 05 December 2011.

Abstract 

Several new treatments for myelodysplastic syndromes (MDS) have recently become available, or are in development. Patients who could benefit from active treatment must be effectively identified and followed up. Therefore, guidelines for the diagnosis and prognostic evaluation of MDS need to be kept up to date with technological and scientific advances. An expert workshop was convened to review currently available and emerging diagnostic technologies and developments in prognostic classification systems, to ensure appropriate management of individual patients. The panel also provided suggestions to ensure adherence to guidelines and highlighted the mandatory requirement for cytogenetic evaluation in patients with MDS.

Keywords: MDS, Diagnosis, Prognosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(11)00537-6

doi:10.1016/j.leukres.2011.11.005

Leukemia Research
Volume 36, Issue 3 , Pages 264-270, March 2012

Article Tools